Colorectal Cancer Clinical Trial
Official title:
Cross-disciplinary Evaluation of Efficacy and Effectiveness of Individualized Complementary Therapies: Evaluating Personalized Effect of Energy Healing as an Individualized Intervention
Verified date | March 2014 |
Source | University of Southern Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Dataprotection Agency |
Study type | Interventional |
Energy healing is among the most commonly used forms of complementary and alternative
medicine among cancer patients. There are, however, few studies on the effects of energy
healing for cancer and cancer associated symptoms and none of them are of a volume or
quality that allows reliable conclusions to be drawn. Qualitative studies on energy healing
in Denmark have demonstrated that the interventions are individualized and the expected
outcomes personalized. This research points to the need for a research design that can
evaluate personalized outcomes of individualized treatments and at the same time adhere to
general demands of external and internal validity.
The objective of this study is to test the effectiveness of energy healing as an
individualized rehabilitative intervention to improve outcomes of personal choice among
persons who have completed a conventional intended curative treatment for colorectal, breast
and prostate cancer. The study is designed as a pragmatic clinical trial with personalized
outcomes.
The study attempts to maximize external validity by using a design that incorporates
important features of energy healing administered in real-life settings: 1a) allowing
participants self-selection to healing and non-healing control, 1b) assessing individual
participant-selected treatment goals, 1c) allowing the treatment to be performed in the
private clinics of the healers. To maximize internal validity similar to that obtained in a
randomized, clinical trial design, the study will 2a) randomize participants to
self-selection and randomized groups of intervention and control; and 2b) supplement the
assessment of personalized treatment goals with assessment of outcomes with standardized
measures.
The study will account for a number of possible moderators of the effects, including 3a)
socio-demographics and 3b) previous experience with complementary and alternative treatment.
Outcome measures will be assessed by questionnaires, physical measurements, data from
administrative registries as well as semi-structured interviews and participant observation.
Possible patterns in the various forms of data will be examined for concordances and
discrepancies.
Finally, the methods will be discussed in terms of their generalizability as a model for
evaluating personal outcomes of individualized treatments with high levels of external and
internal validity.
Status | Completed |
Enrollment | 247 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Primary diagnosis of colorectal, breast and prostate cancer 2. Completed treatment with intended cure and no current cancer Exclusion Criteria: 1. Unwillingness to comply with data collection protocol 2. Mentally and cognitively incapable to participate in the study 3. Poor understanding and expression of the Danish language 4. In palliative care or cancer recurrence prior to inclusion |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Denmark | Christina Gundgaard Pedersen | Aarhus |
Lead Sponsor | Collaborator |
---|---|
University of Southern Denmark | The Ministry of Science, Technology and Innovation, Denmark, University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in personal concerns identified by the patient in the MYCaW questionnaire. | The primary outcome is to investigate whether "energy healing" as an individualized form of treatment can improve personal concerns identified by the patient in the MYCaW questionnaire. | Measured 10 days after baseline, 6 weeks after baseline (before third treatment), 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in Physical Health Survey | Late complications | 10 days, 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in SF-36 Physical activity | Physical activity | 10 days, 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in Facit-sp QoL | Physical, emotional, social and spiritual well-being | Baseline, 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in BDI-II depressive symptoms | Depressive symptoms | Baseline, 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in POMS Mood | Profile of mood states | Baseline, 6 weeks after baseline (before and after third treatment), 10 weeks and 18 weeks after baseline | No |
Secondary | Changes in Daily physical performance | Daily physical performance as reported in diaries | 10 days, 10 weeks and 18 weeks after baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |